CDKN2A and diabetic kidney disease: A clinical trial of the dasatinib and quercetin cocktail demonstrated a decrease in p21 and p16 positive human adipose tissue cells and plasma SASP factors of diabetic kidney disease participants (Hickson et al., 2019).